Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Inclusion Criteria: * Any biopsy or cytologically proven resectable or unresectable primary or secondary (metastatic) malignancy in the lung; this is defined as * Tumors whose only remaining residual deposits are confined to the lungs OR * Oligometastatic tumors with \> 80% of measurable tumor volume in the target lung In both of the above situations, no clinical evidence of central nervous system (CNS) metastases can exist; oligometastatic disease is difficult to define but would, as a guideline, have only 1-4 loci of disease established in 1-2 organ systems outside the affected lung; exceptions to these guidelines can occur, particularly in cases where sites of metastatic disease are equivocal or so minute that it would not exceed 20% of tumor volume * Unresectable stage IV non-small cell lung cancer (NSCLC) * Unresectable stage IIIB NSCLC * Resectable metastatic sarcoma to lung (thoracoscopically resectable) * Other malignancies that meet the criteria * Eastern Cooperative Oncology Group performance status 0-1 * No oxygen needs (oxygen use per standard established criteria for oxygen requirements) * Modified Borg dyspnea scale \< 5 * Six minute walk \>= 50% of the expected distance; this will not be used as exclusion criteria if due to a reason other than respiratory per judgment of physician e.g., pain * Ambulatory and resting oxygen (O2) saturation \> 88% * PPO (predicted post operative)\* forced expiratory volume in one second (FEV1) \>= 50% predicted * PPO values should be calculated for each patient * PPO \* diffusing capacity of the lung for carbon monoxide (DLCO) \>= 50% predicted * PPO values should be calculated for each patient * PPO \* vital capacity \>= 50% predicted * PPO values should be calculated for each patient * Granulocytes \> 1,500 ul * Platelets \>= 100,000 ul * Patients must sign a study-specific consent form prior to registration * Tumor anatomy must allow the isolated lung suffusion in the judgment of the principal investigator (PI) Exclusion Criteria: * Uncontrolled intercurrent disease * Prior chemotherapy for proven metastatic disease within 4 weeks * Evidence of pulmonary toxicity from previous or ongoing chemotherapy * Creatinine \> 1.5 mg/dL * Liver enzymes \> 2 times upper normal * Uncontrolled congestive heart failure (in judgment of the PI) * Optional: ejection fraction \< 40% for clinical evidence of insufficient cardiac reserve (multi gated acquisition scan \[MUGA\] or echocardiogram \[ECHO\] will be done only if indicated in the judgment of the PI) * Myocardial infarction or angina within past 6 months * Contraindications to anticoagulation * Hydration intolerance (e.g., uncontrolled congestive heart failure \[CHF\]) * Human immunodeficiency virus positive (HIV+) on antiretroviral therapy * Pregnant or lactating * Diffuse pulmonary fibrosis involving over 25% of the total lung parenchyma * Previous radiation for thorax * Metastatic sarcoma to lung that is not able to have tumors resected thoracoscopically * Prior lung removal in the affected lung (would have decreased lung volume)